Patent ID: 6451810
Filing Date: 2002-09-17
Classification: A61K,A61P,C07D,Y02A

Abstract:
A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I): whereinR1 is -alkyl-NR3â€”COâ€”R4 or -alkenyl-NR3â€”COâ€”R4 wherein R4 is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl; -alkenyl; -alkynyl; -(alkyl)0-1-aryl; -(alkyl)0-1-(substituted aryl); -(alkyl)0-1-heteroaryl; -(alkyl)0-1-(substituted heteroaryl); â€”O-alkyl; â€”O-(alkyl)0-1-aryl; â€”O-(alkyl)0-1-(substituted aryl); â€”O-(alkyl)0-1-heteroaryl; â€”O-(alkyl)0-1-(substituted heteroaryl); â€”CO-aryl; â€”CO-(substituted aryl); â€”CO-heteroaryl; â€”CO-(substituted heteroaryl); â€”COOH; â€”COâ€”O-alkyl; â€”CO-alkyl; â€”S(O)0-2-alkyl; â€”S(O)0-2-(alkyl)0-1-aryl; â€”S(O)0-2-(alkyl)0-1-(substituted aryl); â€”S(O)0-2-(alkyl)0-1-heteroaryl; â€”S(O)0-2-(alkyl)0-1-(substituted heteroaryl); â€”P(O)(OR3)2; â€”NR3â€”COâ€”O-alkyl; â€”N3; -halogen; â€”NO2; â€”CN; -haloalkyl; â€”O-haloalkyl; â€”CO-haloalkyl; â€”OH; â€”SH; and if R4 is alkyl or alkenyl, then the substituent can also be oxo; or R4 is wherein R5 is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -(substituted aryl); -heteroaryl; -(substituted heteroaryl); -heterocyclyl; -(substituted heterocyclyl); -alkyl-O-alkyl; -alkyl-O-alkenyl; and -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of â€”OH, -halogen; â€”N(R3)2; â€”COâ€”N(R3)2; â€”COâ€”C1-10 alkyl; â€”COâ€”Oâ€”C1-10 alkyl; â€”N3; -aryl; -(substituted aryl); -heteroaryl; -(substituted heteroaryl); -heterocyclyl; -(substituted heterocyclyl); â€”CO-aryl; and â€”CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen; C1-10alkyl-heteroaryl; C1-10 alkyl-(substituted heteroaryl); C1-10 alkyl-aryl; C1-10 alkyl-(substituted aryl) and C1-10 alkyl; n is 0 to 4; and each R present is independently selected from the group consisting of C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, wherein the substituent(s) of the substituted aryl, heteroaryl, and heterocyclyl groups are independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy, nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl, alkanoyloxy, alkanoylthio, and, in the case of a heterocyclyl group, oxo; or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.